Strides Pharma Science Balance Sheet Health
Financial Health criteria checks 2/6
Strides Pharma Science has a total shareholder equity of ₹19.9B and total debt of ₹27.9B, which brings its debt-to-equity ratio to 140.2%. Its total assets and total liabilities are ₹63.4B and ₹43.4B respectively. Strides Pharma Science's EBIT is ₹3.9B making its interest coverage ratio 2. It has cash and short-term investments of ₹3.3B.
Key information
140.2%
Debt to equity ratio
₹27.95b
Debt
| Interest coverage ratio | 2x |
| Cash | ₹3.26b |
| Equity | ₹19.94b |
| Total liabilities | ₹43.44b |
| Total assets | ₹63.38b |
Recent financial health updates
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Recent updates
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11
Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?
Dec 28Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 10Could The Strides Pharma Science Limited (NSE:STAR) Ownership Structure Tell Us Something Useful?
Nov 25Insider Buying: The Strides Pharma Science Limited (NSE:STAR) Non-Executive Director Just Bought 52% More Shares
Aug 17What You Can Learn From Strides Pharma Science Limited's (NSE:STAR) P/E
Aug 11Financial Position Analysis
Short Term Liabilities: STAR's short term assets (₹33.9B) exceed its short term liabilities (₹31.4B).
Long Term Liabilities: STAR's short term assets (₹33.9B) exceed its long term liabilities (₹12.1B).
Debt to Equity History and Analysis
Debt Level: STAR's net debt to equity ratio (123.8%) is considered high.
Reducing Debt: STAR's debt to equity ratio has increased from 113.2% to 140.2% over the past 5 years.
Debt Coverage: STAR's debt is not well covered by operating cash flow (14%).
Interest Coverage: STAR's interest payments on its debt are not well covered by EBIT (2x coverage).